These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37633047)

  • 61. Electrophilic characteristics and aqueous behavior of fatty acid nitroalkenes.
    Grippo V; Mojovic M; Pavicevic A; Kabelac M; Hubatka F; Turanek J; Zatloukalova M; Freeman BA; Vacek J
    Redox Biol; 2021 Jan; 38():101756. PubMed ID: 33181478
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Single Nucleotide Polymorphisms (SNPs) of RAD51-G172T and XRCC2-41657C/T Homologous Recombination Repair Genes and the Risk of Triple- Negative Breast Cancer in Polish Women.
    Michalska MM; Samulak D; Romanowicz H; Smolarz B
    Pathol Oncol Res; 2015 Sep; 21(4):935-40. PubMed ID: 25743260
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Histone deacetylase inhibitor 2-hexyl-4-pentynoic acid enhances hydroxyurea therapeutic effect in triple-negative breast cancer cells.
    Ding C; Su B; Li Q; Ding W; Liu G; Cai Z; Zhang F; Lim D; Feng Z
    Mutat Res Genet Toxicol Environ Mutagen; 2022 Jan; 873():503422. PubMed ID: 35094806
    [TBL] [Abstract][Full Text] [Related]  

  • 64. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair.
    Kong Y; Xu C; Sun X; Sun H; Zhao X; He N; Ji K; Wang Q; Du L; Wang J; Zhang M; Liu Y; Wang Y; Liu Q
    Cancer Biol Med; 2021 Dec; 19(8):1150-71. PubMed ID: 34846107
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
    Tahara M; Inoue T; Sato F; Miyakura Y; Horie H; Yasuda Y; Fujii H; Kotake K; Sugano K
    Mol Cancer Ther; 2014 May; 13(5):1170-80. PubMed ID: 24577941
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
    Llop-Guevara A; Loibl S; Villacampa G; Vladimirova V; Schneeweiss A; Karn T; Zahm DM; Herencia-Ropero A; Jank P; van Mackelenbergh M; Fasching PA; Marmé F; Stickeler E; Schem C; Dienstmann R; Florian S; Nekljudova V; Balmaña J; Hahnen E; Denkert C; Serra V
    Ann Oncol; 2021 Dec; 32(12):1590-1596. PubMed ID: 34520831
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
    Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
    Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Inhibition of homologous recombination by treatment with BVDU (brivudin) or by RAD51 silencing increases chromosomal damage induced by bleomycin in mismatch repair-deficient tumour cells.
    Vernole P; Muzi A; Volpi A; Dorio AS; Terrinoni A; Shah GM; Graziani G
    Mutat Res; 2009 May; 664(1-2):39-47. PubMed ID: 19428379
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Triumphs and challenges in exploiting poly(ADP-ribose) polymerase inhibition to combat triple-negative breast cancer.
    Wooten J; Mavingire N; Damar K; Loaiza-Perez A; Brantley E
    J Cell Physiol; 2023 Aug; 238(8):1625-1640. PubMed ID: 37042191
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment.
    Naipal KA; Verkaik NS; Ameziane N; van Deurzen CH; Ter Brugge P; Meijers M; Sieuwerts AM; Martens JW; O'Connor MJ; Vrieling H; Hoeijmakers JH; Jonkers J; Kanaar R; de Winter JP; Vreeswijk MP; Jager A; van Gent DC
    Clin Cancer Res; 2014 Sep; 20(18):4816-26. PubMed ID: 24963051
    [TBL] [Abstract][Full Text] [Related]  

  • 71. An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.
    Shah MM; Dobbin ZC; Nowsheen S; Wielgos M; Katre AA; Alvarez RD; Konstantinopoulos PA; Yang ES; Landen CN
    Gynecol Oncol; 2014 Aug; 134(2):331-7. PubMed ID: 24844596
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Common fragile sites in colon cancer cell lines: role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1.
    Vernole P; Muzi A; Volpi A; Terrinoni A; Dorio AS; Tentori L; Shah GM; Graziani G
    Mutat Res; 2011 Jul; 712(1-2):40-8. PubMed ID: 21570414
    [TBL] [Abstract][Full Text] [Related]  

  • 73. SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers.
    Lu Z; Mao W; Yang H; Santiago-O'Farrill JM; Rask PJ; Mondal J; Chen H; Ivan C; Liu X; Liu CG; Xi Y; Masuda K; Carrami EM; Chen M; Tang Y; Pang L; Lakomy DS; Calin GA; Liang H; Ahmed AA; Vankayalapati H; Bast RC
    J Clin Invest; 2022 Jun; 132(11):. PubMed ID: 35642638
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibition of homologous recombination in human cells by targeting RAD51 recombinase.
    Huang F; Mazina OM; Zentner IJ; Cocklin S; Mazin AV
    J Med Chem; 2012 Apr; 55(7):3011-20. PubMed ID: 22380680
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
    Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
    Xie X; He G; Siddik ZH
    Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Atmospheric-pressure plasma jet induces DNA double-strand breaks that require a Rad51-mediated homologous recombination for repair in Saccharomyces cerevisiae.
    Lee Y; Kim K; Kang KT; Lee JS; Yang SS; Chung WH
    Arch Biochem Biophys; 2014 Oct; 560():1-9. PubMed ID: 25086216
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
    Wilson AJ; Sarfo-Kantanka K; Barrack T; Steck A; Saskowski J; Crispens MA; Khabele D
    Gynecol Oncol; 2016 Oct; 143(1):143-151. PubMed ID: 27444036
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody.
    Song H; Hedayati M; Hobbs RF; Shao C; Bruchertseifer F; Morgenstern A; Deweese TL; Sgouros G
    Mol Cancer Ther; 2013 Oct; 12(10):2043-54. PubMed ID: 23873849
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Inhibiting homologous recombination by targeting RAD51 protein.
    Demeyer A; Benhelli-Mokrani H; Chénais B; Weigel P; Fleury F
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188597. PubMed ID: 34332021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.